Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2015-03-16 Director's Dealing
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2015-03-16 English
ANNUAL REPORT
Annual Report FY 2014
2015-03-16 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 26, 2015. It reports an amendment to the Certificate of Incorporation related to the board structure and classified board provisions. The content focuses on corporate governance changes, specifically amendments to articles of incorporation and board provisions. There are no financial statements or earnings data, no audit information, no voting results, no dividend announcements, no merger or acquisition details, and no investor presentation content. The document is a regulatory filing reporting a corporate governance change, which fits the category of Board/Management Information (MANG). The document length is 4146 characters, which is short but contains substantive information about board changes, not just an announcement of a report. Therefore, the best classification is MANG with high confidence.
2015-03-04 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering. It details the offering of common stock and warrants, underwriting information, risk factors, use of proceeds, and other related information typical of a capital raising document. It is not a financial report, earnings release, or management discussion. The presence of terms like 'Prospectus Supplement', 'Registration No.', 'Offering Price', 'Underwriting Discounts', and detailed securities offering terms clearly indicate this is a capital/financing update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2015-02-06 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Actinium Pharmaceuticals, Inc. It details the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock and warrants. The document includes descriptions of the offering terms, underwriting agreement, and related exhibits such as the warrant form and legal opinion. There are no financial statements or comprehensive financial data typical of annual or interim reports. The content focuses on financing activities and capital raising. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length (7142 characters) and detailed description of the offering confirm it is not merely an announcement but a substantive filing about financing activity.
2015-02-06 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text specifically mentions a press release announcing a proposed public offering of common stock and warrants, which is a financing activity. The document is short (2411 characters) and includes a press release as an exhibit. This fits the category of a Capital/Financing Update rather than a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-02-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.